Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
36 hedge funds and large institutions have $296M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
13% more funds holding
Funds holding: 32 → 36 (+4)
12% more capital invested
Capital invested by funds: $264M → $296M (+$32.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$12.7M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$2.61M |
| 3 |
Janus Henderson Group
London,
|
+$1.15M |
| 4 |
BlackRock
New York
|
+$1.14M |
| 5 |
State Street
Boston,
Massachusetts
|
+$637K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.94M |
| 2 |
ZP
Zimmer Partners
New York
|
-$1.97M |
| 3 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$1.2M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.13M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$786K |
STSA Hedge Fund Activity: Q1 2020 in Review
36 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q1 2020, worth a combined $296M — up 12% from $264M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new STSA positions and 2 closed out — a net gain of 4 holders — while 15 added to existing stakes and 9 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $12.7M. The largest seller was Wellington Management Group, cutting an estimated $5.94M.
- 36 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q1 2020, up from 32 in Q4 2019.
- Funds reported $296M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q1 2020, up 12% quarter-over-quarter.
- 6 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q1 2020 and 2 closed out, a net change of +4 holders.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Eventide Asset Management, an estimated $12.7M added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q1 2020 was Wellington Management Group, an estimated $5.94M sold.
Based on aggregated 13F filings for Q1 2020.